郑州做飞秒激光手术对眼睛好吗(郑州可以做近视手术的医院) (今日更新中)

THE HAGUE, June 24 (Xinhua) -- Bird flu was discovered at a poultry farm in the central Dutch province of Flevoland, the Ministry of Agriculture said Friday.It said the virus discovered was a mild variant. The farm's 47,000 chickens were slaughtered to prevent the virus turning into a contagious and deadly variant.It remains uncertain whether the chickens were infected with the high or low pathologene H7 variant. The low pathologene version can mutate into a high pathologen, which is extremely transmittable.Poultry from other farms in a zone of three kilometres of the contaminated farm will be tested. A prohibition of transport for poultry, eggs and poultry manure has been set.

BEIJING, July 11 (Xinhuanet) -- The pace of China's import growth in June fell to its lowest level in 20 months as tightening monetary policies kicked in, resulting in the biggest monthly trade surplus this year, official statistics show.Import growth is expected to slow in the coming months, thanks to the broad impact of the tightening measures, before picking up in the last quarter, economists predicted.According to the General Administration of Customs (GAC), imports rose 19.3 percent, from a year earlier, to 9.7 billion, the weakest since November 2009.Exports rose 17.9 percent and despite this being the smallest increase since last December they reached a record high of 1.9 billion.The decline in import growth has led to a widening trade surplus, .3 billion in June compared to .1 billion in May. But in the first six months the trade surplus dropped 18 percent, year-on-year, to .9 billion."Import growth was weaker than expected, as imports for China's processing trade weakened and de-stocking in heavy industry continued," Wang Tao, head of China Economic Research at UBS Securities, said."Recent commodity price drops, including crude oil, also helped lower the import bill," she added.June's net imports of crude oil fell 12 percent from May to 19.43 million metric tons, the lowest since October, amid refinery maintenance and slowing energy demand, according to the GAC figures."Decelerating economic growth and tightening measures to soak up market liquidity have reined in import growth, but it is not a cause for worry," Li Wei, an economist at Standard Chartered Shanghai, said.The government is expected to announce economic growth data for the second quarter on Wednesday. Gross domestic product growth is widely predicted to slow from 9.7 percent for the first quarter."The slowdown in import growth will last two to three months or even longer due to both falling demand and possible commodity price drops," Li said.Zhong Shan, vice-minister of commerce, said recently that imports will slow down in the second half, citing the government's measures to cool the economy.The central bank has raised interest rates five times since mid-October, with the latest on July 7, and increased the reserve requirements for commercial banks, the amount they have to set aside, nine times since November. The consumer price index, a major gauge of inflation, surged to 6.4 percent last month, the highest in three years.Zhao Fudi, GAC spokesman, said in an online broadcast on Sunday that higher prices are increasing inflationary pressure, leading to a 14.7 percent gain in the overall price of imported commodities in the first half.Imports surged 27.6 percent year-on-year to 9.4 billion from January to June, as commodity prices rose during the first half. Exports increased 17.9 percent in June, down from 19.4 percent in May."This is because of weaker external demand" from developed nations, Wang said.Exports increased 24 percent, year-on-year, to 4.3 billion during the first half, but exports to both the United States and the European Union, China's two major trading partners, rose by only 16.9 percent."The slow recovery of the global economy and the European debt crisis have added uncertainties to export growth," Zheng Yuesheng, head of the GAC statistics department, said.Lu Zhengwei, chief economist at Industrial Bank, believes that the March earthquake and tsunami in Japan hurt China's exports."The disaster cut off China's imports of parts and components used for mechanical and electrical goods, leading to a decline in those exports" which make up a majority of China's exports, Lu said.As Japanese manufacturers resume full production, or come close to it, in September, China's exports will regain momentum, he predicted.Li Wei agreed. "China's exports keep pace with the global economic recovery. And growth will probably see a turnaround in September" when orders for the Christmas season are usually made, Li said.Many companies in China's coastal regions are far from optimistic, citing rising costs in labor and raw materials and yuan appreciation, as well as shrinking demand abroad.Han Jie, deputy director general of the department of commerce in Zhejiang province, said "exporters in Zhejiang have experienced a disappointing first half, and the second half will not be better".

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

CANBERRA, Aug. 31 (Xinhua) -- Australia's new chief medical officer, Professor Chris Baggoley, on Wednesday said Australian should not be worried about reports that a mutant strain of the deadly bird flu virus is spreading across Asia and beyond.On Monday, the UN's Food and Agriculture Organization (FAO) said a mutant strain of the deadly avian influenza virus was spreading in Asia and issued a warning that the bird flu could spread from poultry to humans. It urged "heightened readiness and surveillance" as the mutant strain posed "unpredictable risks to human health."But Professor Baggoley, who took office on Tuesday, said Australia is well served by strict testing and customs regimes, adding that avian migration patterns also mean infected birds are highly unlikely to arrive in Australia."I don't think we should be worried," Prof Baggoley told Sky News."The country and the Australian government is certainly vigilant in relation to bird flu."Prof. Baggoley insisted the H5N1 virus remains overwhelmingly a disease of birds and it is very uncommon for humans to catch it. It is also exceedingly rare for humans to spread it among themselves.He said that even if bird flu did arrive and affected humans, Australia is ready to respond to any new and significant developments in bird flu."Australia tests migratory wild birds, looking for H5N1, and has been doing this for some years and has never found it," he said."On the human side of things, Australia has been preparing for a possible outbreak of H5N1 since 2004."We've got the laboratory capacity to diagnose influenza; we've got arrangements in place for a rapid production of an H5N1 vaccine for humans, and we've got ready access to antivirals."There have been no outbreaks of bird flu in Australia to date.The UN said the latest human death from bird flu occurred earlier this month in Cambodia, which has registered eight cases of human infection this year, all of them fatal.H5N1 has infected 565 people since it first appeared in 2003, killing 331.

来源：资阳报